HALFLYTELY
LOE Approachingbisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
NDAORALFOR SOLUTION, TABLET, DELAYED RELEASE
Approved
May 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALFLYTELY is a bowel preparation solution combining polyethylene glycol 3350 with electrolytes (potassium chloride, sodium bicarbonate, sodium chloride) and bisacodyl delayed-release tablets for colonic cleansing. It is indicated for patients undergoing colonoscopy or other procedures requiring bowel evacuation. The PEG-based osmotic laxative works by drawing water into the colon while bisacodyl stimulates intestinal motility.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30 relative score), suggesting team consolidation and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing
Started Sep 2011
2,154 enrolled
Colon Cleansing
Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep
Started May 2010
608 enrolled
Bowel Preparation
Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep
Started May 2010
603 enrolled
Bowel Preparation
Career Relevance
Working on HALFLYTELY offers limited growth trajectory given LOE-approaching status and zero linked job openings, making this a consolidation/wind-down assignment rather than a growth opportunity. Career value lies in managed decline expertise, generic transition planning, and patient access strategy—skills transferable to other maturing products.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.